Nano Pharmaceuticals
Market Cap
₹133 ₹133 Cr.
P/E
44.44
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
-
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
23.25 %
Institutions
Institutions
-
Market cap
Market cap
133 Cr
No. of Shareholders
No. of Shareholders
8,038
OPM (%)
OPM (%)
8.41 %
PE
PE
44.44
Prom Holding
Prom Holding
-
ROCE (%)
ROCE (%)
1.24
ROE (%)
ROE (%)
0.97
Sales
Sales
46.35 Cr
  • Guj. Inject (Kerala)
  • HR Hygiene Products
  • Auro Laboratories
Last updated on 5 Oct 2026
  • Gujarat Inject (Kerala) is a diversified trading company with one reportable segment and FY26 revenue of ₹36.32Cr. Its mix has shifted sharply to distributing Solar PV modules — power-generation panels — to named solar customers.
  • It is pivoting to clean energy. Its objects now allow power generation, battery storage and EV charging, and a rename to Regenova Renewtech is proposed.
  • About ₹35Cr of named solar orders is disclosed against FY26 revenue of ₹36.32Cr; the largest single order is ₹14.49Cr. Revenue is lumpy and order-delivery-led.
  • A ₹20.76Cr solar power generation project is under construction, about 57% of FY26 revenue. A separate energy-storage partnership with England-based Storenergy remains at evaluation.
  • Q1FY27 revenue was 44% of the Q4FY26 peak, yet PAT was 68% of full-year FY26 PAT. Profit held up better than revenue.
  • FY26 operating cash flow of ₹21.22Cr came mainly from an ₹18.58Cr rise in trade payables. Cash generation is execution-sensitive while payables stay elevated.
  • The phase is solar-order execution plus a pre-revenue solar-asset build. Earnings hinge on converting the order pool and paying the project seller to unlock cash.
  • The Soleos solar agreement, signed Jun 2025, was disclosed only in Oct 2026. A formal chairman designation remains unfiled after the chairman died in June.
  • Zentaraa module order execution Oct 2026
    the ₹4.86Cr, 3,600-module order is due; delivery would start converting the disclosed order pool into revenue.
  • First full quarter after the order surge ~mid-Nov 2026
    results will show whether disclosed solar orders convert to revenue and whether the Q4FY26 delivery lumpiness repeats.
  • Solar project commissioning no stated COD
    ₹20.76Cr of work-in-progress yields no revenue or cash until consideration is paid to Soleos Energy, the project counterparty. The 5MW Jakasana project's status is unconfirmed.
  • Storenergy energy-storage framework no stated timeline
    commercial terms are deferred per project; any filed order, revenue or capex would be the first for the storage business.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
2
52W Range
High
14
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

3 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Gujarat Inject (Kerala) Ltd. Business

Tarajyot Polymers Ltd, a subsidiary of the Government of Kerala, specializes in the production and distribution of pharmaceutical products and medical equipment. They offer a wide range of items including bulk drugs, formulation chemicals, intravenous fluids, and disposable medical instruments.

Guj. Inject (Kerala) major competitors are Lactose (India), Panchsheel Organics, Parnax Lab, Speciality Medicines, Godavari Drugs, Alpa Laboratories, HR Hygiene Products.
Market Cap of Guj. Inject (Kerala) is ₹134 Crs.
While the median market cap of its peers are ₹133 Crs.

Guj. Inject (Kerala) seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release May Jul
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material